Nivolumab
Solid Tumour
Presage Biosciencesmonoclonal_antibodyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the Solid Tumour cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Henlix, Inc | Phase 2 | B |
Atezolizumab Genentech, Inc. | Phase 2/3 | B |
ALECTINIB Cancer Research UK | Phase 2/3 | B |
Entrectinib Cancer Research UK | Phase 2/3 | B |
Dabrafenib Cancer Research UK | Phase 2/3 | B |
View all 36 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →